Big pharmaceutical companies create the medications that keep countless people around the world healthy, but that hasn’t helped their ailing stock prices this year. The U.K.-based AstraZeneca has been no exception, but its shares could get a shot in the arm in 2024, Teresa Rivas writes in this week’s edition of Barron’s. Consensus estimates call for the company to deliver double-digit earnings growth — roughly 14% and 15% in 2024 and 2025, respectively — driven by a diverse portfolio of blockbusters, the author says. AstraZeneca also has results due from any number of clinical trials that could provide catalysts for the stock. Shares also look reasonably priced heading into the new year, the publication adds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AZN:
- AstraZeneca looks much better heading into 2024, Barron’s says
- Gracell downgrade, Fusion upgrade: Wall Street’s top analyst calls
- Gracell price target raised to $10 from $7 at Wells Fargo
- Gracell downgraded to Neutral from Overweight at Piper Sandler
- M & A News: Bristol-Myers Squibb (NYSE:BMY) to Buy RayzeBio for $4.1B